At least, that’s the case with Bristol Myers Squibb ( BMY +0.74%), Pfizer ( PFE +1.41%), and Dentsply Sirona ( XRAY 1.37%). Each has a high yield and a poor near-term track record of price performance, but may prove a worthwhile buy at the current price.
3 Healthcare Stocks Topping a 2025 List of Dividend Yields
view original post